Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ethicon builds women’s health business

This article was originally published in The Gray Sheet

Executive Summary

Johnson & Johnson/Ethicon completed its acquisition of uterine fibroid treatment developer Vascular Control Systems on May 9. Ethicon picks up Flostat, which is a minimally invasive alternative for uterine artery occlusion, and Cstat, a guided hemostat to control blood loss during open surgeries. On May 11, the J&J division announced it had received a CE mark for its female stress urinary incontinence treatment TVT Secur. The device, which can be implanted under local anesthesia, uses J&J's Prolene mesh to create a mid-urethral sling...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT023543

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel